News

Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.
Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions"
NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by ...
A new shot prevents HIV—and breathes new life into a stagnant biotech
Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...
Long-lasting HIV prevention shot headed toward approval
FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
Walmart's Flipkart has secured a lending licence from the Indian central bank and banking regulator, enabling it to offer ...
2 Reasons to Like GILD (and 1 Not So Much)
While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...
Long-lasting HIV prevention shot heads toward approval
A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.
Gilead Sciences' Best Days May Be Ahead - Here's Why
Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...
Morgan Stanley Reaffirms Overweight on Gilead Sciences, Inc. (GILD), Citing LEN Potential
On Monday, analysts at Morgan Stanley reiterated their Overweight rating on Gilead Sciences, Inc. (NASDAQ:GILD), while ...
Investing12d
Gilead Sciences’ SWOT analysis: HIV giant faces oncology growth, patent cliff
Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical powerhouse known for its innovative HIV treatments, is navigating a complex landscape of opportunities and challenges as it seeks to ...
Jefferies Maintains Buy Rating on Gilead Sciences (GILD), Cites Robust Pipeline
Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...
Stocktwits on MSN9d
Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance
Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...